Astellas Pharma Inc. (TYO:4503)
1,633.00
+9.50 (0.59%)
Oct 27, 2025, 1:45 PM JST
Astellas Pharma Revenue
Astellas Pharma had revenue of 505.79B JPY in the quarter ending June 30, 2025, with 6.91% growth. This brings the company's revenue in the last twelve months to 1.94T, up 14.29% year-over-year. In the fiscal year ending March 31, 2025, Astellas Pharma had annual revenue of 1.91T with 19.25% growth.
Revenue (ttm)
1.94T
Revenue Growth
+14.29%
P/S Ratio
1.49
Revenue / Employee
142.56M
Employees
13,643
Market Cap
2.91T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.91T | 308.65B | 19.25% |
| Mar 31, 2024 | 1.60T | 85.05B | 5.60% |
| Mar 31, 2023 | 1.52T | 222.46B | 17.16% |
| Mar 31, 2022 | 1.30T | 46.64B | 3.73% |
| Mar 31, 2021 | 1.25T | -51.32B | -3.94% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.48T |
| Otsuka Holdings | 2.40T |
| Daiichi Sankyo Company | 1.92T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.04T |
| Olympus | 969.02B |
| HOYA Corporation | 876.09B |
| Eisai | 803.02B |
Astellas Pharma News
- 3 days ago - Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA) - PRNewsWire
- 4 days ago - Astellas Pharma Announces Encouraging Data From OPTION-VMS Phase IV Study - Nasdaq
- 4 days ago - Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study - PRNewsWire
- 5 days ago - PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer - Benzinga
- 7 days ago - Astellas Reports Sustained GA Reduction With Long-Term IZERVAY Treatment In GATHER2 Extension Study - Nasdaq
- 8 days ago - Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients - Reuters
- 8 days ago - Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients - Investor's Business Daily
- 8 days ago - PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer - Benzinga